CD4/CD8 Ratio Predicts Survival in Ovarian Cancer Patients Who Don't Respond to Peptide Vaccine | Research

The takeaway

Among peptide vaccine-treated ovarian cancer patients who don't develop IgG antibody responses, the CD4/CD8 T cell ratio serves as an alternative biomarker predicting survival.

Alternative biomarker
CD4/CD8 ratio predicts survival specifically in peptide vaccine patients who don't develop antibody responses

What the researchers found

The CD4/CD8 T cell ratio is a prognostic factor for IgG nonresponders among peptide vaccine-treated ovarian cancer patients, identifying survivors who benefit despite no antibody response.

Why it matters

Identifying biomarkers for patients who benefit from immunotherapy without traditional response markers is crucial for treatment decisions and avoiding premature treatment cessation.

The numbers in context

n=25 IgG nonresponders; ↑CD8 (n=7) vs ↓CD8 (n=18) p=0.018; ↓CD4/CD8 (n=10) vs ↑ (n=15) p=0.0055

How the study worked

Retrospective analysis of ovarian cancer patients treated with personalized peptide vaccination, biomarker analysis of IgG nonresponders.

Who was studied

25 IgG-nonresponder patients with advanced/recurrent ovarian cancer treated with personalized peptide vaccination

What this study cannot tell us

Retrospective analysis with limited sample size. The CD4/CD8 ratio is a general immune marker, not specific to tumor-reactive T cells.

How to read the evidence

Retrospective biomarker analysis. Hypothesis-generating but needs prospective validation.

When this study was published

Published in 2020.

The bigger picture

This study highlights that peptide vaccine efficacy may work through cellular immunity (T cells) even when humoral immunity (antibodies) doesn't respond, informing how we monitor immunotherapy success.

Questions still open

Should IgG nonresponders continue peptide vaccination if their CD4/CD8 ratio is favorable?
Can CD4/CD8 ratio guide treatment decisions across cancer types?
What alternative immune mechanisms drive survival in IgG nonresponders?

Common questions

Why don't all cancer patients respond to peptide vaccines?

Immune responses vary between individuals. Some patients produce antibodies (IgG) against vaccine peptides, which correlates with better survival. But others may benefit through T cell-mediated responses that standard antibody tests don't detect.

What is the CD4/CD8 ratio?

It's the ratio of helper T cells (CD4) to killer T cells (CD8) in the blood. This study found it predicts survival in vaccine patients who don't make antibodies, suggesting T cell balance matters for immune-mediated anti-cancer effects.

Read the original research

CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine-treated ovarian cancer patients.

Cancer science, 111(4), 1124-1131

View on PubMed ↗Publisher’s paper ↗

Citation

Waki, Kayoko; Kawano, Kouichiro; Tsuda, Naotake; Komatsu, Nobukazu; Yamada, Akira. (2020). CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine-treated ovarian cancer patients.. Cancer science, 111(4), 1124-1131. https://doi.org/10.1111/cas.14349